PROSCA/BLADDR 2023 | Unraveling grading challenges in bladder tumors

Eva Compérat, MD, PhD, Medical University of Vienna in Austria, discusses challenges in grading bladder tumors. While international standards, such as those established by the World Health Organization (W.H.O.) in 2004, classify tumors into low and high grades, mixed tumors with both components exist. The W.H.O. guidelines specify that if a tumor has more than 5% high-grade components, it should be considered high grade. However, EU guidelines, influenced by urology research, recommend a hybrid system causing confusion. Prof. Compérat emphasizes the need for a universally applicable system, especially as many pathologists handle various types of pathology and anticipates that artificial intelligence (AI) will play a significant role in refining classifications in the future. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws and treaties globally. All rights are reserved.